Part 2 Mini case: Per the 12C2 embedded clinics/pharmacies (ECP) business case (page 509), 12C2 is considering a series of enhancements to this existing system. In planning discussions with 12C2 business and IT team members, the following points were captured in the meeting minutes. Complete the following for each of these points: (1) Determine if the item is a risk, and issue, an assumption, or a constraint. (2) For risks and issues, determine the level of impact (high, medium, or low) and relate it to a corresponding item in Table 12-2. (3) For risks, determine the level of probability (high, medium, or low) and your preferred mitigation strategy (avoidance, limitation, transference, or acceptance). For each item, explain your answers. Look for downdown selections in first three answer cells 2 3 If a risk or Preferred Questions Type issue: mitigation Explain your choices (select 1) determine strategy level 1. Given the dozen countries in which 12C2 operates clinicsipharmacies, management decided to let three senior pharmacy leaders in Mexico, Ethiopia, and Malaysia be product owners on behalf of the rest of the world. 2. The prior point did raise a concern that those three leaders might not be able to speak for users in the other nine countries, given differences in legal regulations and market practices in different parts of the world. 3. Further, it was just determined that one of those three senior pharmacy leaders will be going out on paternity leave for two months. 4. In discussing the sharing drugs" feature, there was some disagreement regarding whether 12C2 pharmacies should be able to share drugs across national borders. In several geographically small countries in Central America, pharmacists noted that 12C2 pharmacies in different countries were only a few miles apart. The cost-estimation impacts of this could be 5. For sharing drugs and consolidated purchasing the system is currently built with each pharmacy running its own instance of the system using a local database. This will necessitate implementing a new architecture using a centralized database, either replacing the existing locall databases or maintaining copies of that data. 6. The 12C2 team has historically underestimated the time and cost needed to develop features. Because of this, the CO is requiring improved training on project estimation, planning, and management 7. Also, the CIO noted that 12C2 has historically utilized several key outside contractors, each of whom understands the 12C2 pharmacy system thoroughly. However, because 12C2 hasn't used those contractors for almost a year, it is not clear if they will be available for this project 8. This project cannot start for another six weeks, while the development team finishes up another, unrelated project that is occupying them full-time. Part 2 Mini case: Per the 12C2 embedded clinics/pharmacies (ECP) business case (page 509), 12C2 is considering a series of enhancements to this existing system. In planning discussions with 12C2 business and IT team members, the following points were captured in the meeting minutes. Complete the following for each of these points: (1) Determine if the item is a risk, and issue, an assumption, or a constraint. (2) For risks and issues, determine the level of impact (high, medium, or low) and relate it to a corresponding item in Table 12-2. (3) For risks, determine the level of probability (high, medium, or low) and your preferred mitigation strategy (avoidance, limitation, transference, or acceptance). For each item, explain your answers. Look for downdown selections in first three answer cells 2 3 If a risk or Preferred Questions Type issue: mitigation Explain your choices (select 1) determine strategy level 1. Given the dozen countries in which 12C2 operates clinicsipharmacies, management decided to let three senior pharmacy leaders in Mexico, Ethiopia, and Malaysia be product owners on behalf of the rest of the world. 2. The prior point did raise a concern that those three leaders might not be able to speak for users in the other nine countries, given differences in legal regulations and market practices in different parts of the world. 3. Further, it was just determined that one of those three senior pharmacy leaders will be going out on paternity leave for two months. 4. In discussing the sharing drugs" feature, there was some disagreement regarding whether 12C2 pharmacies should be able to share drugs across national borders. In several geographically small countries in Central America, pharmacists noted that 12C2 pharmacies in different countries were only a few miles apart. The cost-estimation impacts of this could be 5. For sharing drugs and consolidated purchasing the system is currently built with each pharmacy running its own instance of the system using a local database. This will necessitate implementing a new architecture using a centralized database, either replacing the existing locall databases or maintaining copies of that data. 6. The 12C2 team has historically underestimated the time and cost needed to develop features. Because of this, the CO is requiring improved training on project estimation, planning, and management 7. Also, the CIO noted that 12C2 has historically utilized several key outside contractors, each of whom understands the 12C2 pharmacy system thoroughly. However, because 12C2 hasn't used those contractors for almost a year, it is not clear if they will be available for this project 8. This project cannot start for another six weeks, while the development team finishes up another, unrelated project that is occupying them full-time